Alnylam Promotes Pushkal Garg to Chief Research and Development Officer

Details

announced the combination of its Research and Early Development function and its Development function into a single organization. The People, Culture and Compensation Committee approved the appointment of Pushkal Garg, M.D., as Executive Vice President, Chief Research and Development Officer, and expanded the responsibilities of Kevin Fitzgerald, Ph.D., to include external innovation. Additionally, the committee approved changes to the compensation of both executives.

Items reported

Exhibits (1)

About Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.